日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer.

靶向 MKK3/c-Myc 相互作用以克服 EGFR 突变肺癌中奥希替尼的获得性耐药性。

期刊:Cancer Letters
影响因子:10.1
doi:10.1016/j.canlet.2025.218010
Chen Zhen, Vallega Karin A, Wang Dongsheng, Bildtsen Elsa, Fu Haian, Ramalingam Suresh S, Ivanov Andrey A, Sun Shi-Yong
肺癌
肿瘤
EGF
MYC
EGFR
发表日期：2025
文献求助 收藏

DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models

DNA 拓扑异构酶 II 抑制增强奥希替尼对 EGFR 突变非小细胞肺癌模型的治疗效果

期刊:Journal of Clinical Investigation
影响因子:13.3
doi:10.1172/JCI172716
Zhen Chen, Karin A Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang, Ticiana Leal, Suresh S Ramalingam, Shi-Yong Sun
肿瘤
肺癌
其它细胞
Human
发表日期：2024
文献求助 收藏

Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer.

奥希替尼通过抑制hTERT/端粒酶/端粒发挥治疗EGFR突变型肺癌的疗效

期刊:Journal of Experimental Medicine
影响因子:10.6
doi:10.1084/jem.20240435
Chen Zhen, Vallega Karin A, Wang Dongsheng, Quan Zihan, Fan Songqing, Wang Qiming, Leal Ticiana, Ramalingam Suresh S, Sun Shi-Yong
肿瘤
EGFR
肿瘤免疫
发表日期：2024
文献求助 收藏

Targeting Transient Receptor Potential Melastatin-2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer

靶向瞬时受体电位黑素-2（TRPM2）增强第三代EGFR抑制剂对EGFR突变型肺癌的治疗效果

期刊:Advanced Science
影响因子:
doi:10.1002/advs.202310126
Zhen Chen, Karin A Vallega, Vijay K Boda, Zihan Quan, Dongsheng Wang, Songqing Fan, Qiming Wang, Suresh S Ramalingam, Wei Li, Shi-Yong Sun
肿瘤
肺癌
发表日期：2024
文献求助 收藏

The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition

天然产物小檗碱与奥希替尼协同作用，通过直接抑制 MET 优先对抗 MET 扩增的奥希替尼耐药肺癌

期刊:Pharmacological Research
影响因子:9.1
doi:10.1016/j.phrs.2021.105998
Zhen Chen, Karin A Vallega, Haiying Chen, Jia Zhou, Suresh S Ramalingam, Shi-Yong Sun
肿瘤
肺癌
FCM
IF
IHC-P
WB
Human
发表日期：2022
文献求助 收藏

Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both

通过抑制 Mcl-1、激活 Bax 或两者同时激活内在凋亡途径，克服对第三代 EGFR 抑制剂的获得性耐药性

期刊:Oncogene
影响因子:6.9
doi:10.1038/s41388-022-02200-5
Guangzhi Ma, Yunfu Deng, Luxi Qian, Karin A Vallega, Guojing Zhang, Xingming Deng, Taofeek K Owonikoko, Suresh S Ramalingam, Douglas D Fang, Yifan Zhai, Shi-Yong Sun
信号转导
细胞生物学
Apoptosis
发表日期：2022
文献求助 收藏

Macrophage-Conditioned Media Promotes Adipocyte Cancer Association, Which in Turn Stimulates Breast Cancer Proliferation and Migration.

巨噬细胞条件培养基促进脂肪细胞癌变，进而刺激乳腺癌增殖和迁移

期刊:Biomolecules
影响因子:4.8
doi:10.3390/biom12121757
Vallega Karin A, Bosco Dale B, Ren Yi, Sang Qing-Xiang Amy
细胞生物学
乳腺癌
发表日期：2022
文献求助 收藏

Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors

膜相关 RING-CH 8 作为一种新型 PD-L1 E3 连接酶发挥作用，介导 EGFR 抑制剂诱导的 PD-L1 降解

期刊:Molecular Cancer Research
影响因子:4.1
doi:10.1158/1541-7786.MCR-21-0147
Guoqing Qian, Jianping Guo, Karin A Vallega, Changjiang Hu, Zhen Chen, Yunfu Deng, Qiming Wang, Songqing Fan, Suresh S Ramalingam, Taofeek K Owonikoko, Wenyi Wei, Shi-Yong Sun
信号转导
发表日期：2021
文献求助 收藏

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling

通过共同靶向MEK/ERK信号通路来管理对第三代EGFR酪氨酸激酶抑制剂的获得性耐药性

期刊:Lung Cancer: Targets and Therapy
影响因子:3.3
doi:10.2147/LCTT.S293902
Yu, Danlei; Zhao, Wen; Vallega, Karin A; Sun, Shi-Yong
信号转导
EGFR
EGF
MAPK/ERK
发表日期：2021
文献求助 收藏

Hospital-Acquired SARS-Cov-2 Infections in Patients: Inevitable Conditions or Medical Malpractice?

医院内感染SARS-CoV-2病毒：是不可避免的情况还是医疗事故？

期刊:International Journal of Environmental Research and Public Health
影响因子:
doi:10.3390/ijerph18020489
Barranco, Rosario; Vallega Bernucci Du Tremoul, Luca; Ventura, Francesco
炎症/感染
SARS-CoV-2
微生物学
发表日期：2021
文献求助 收藏